Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report.
The purpose of this study was to evaluate if synbiotic therapy can correct the deteriorated gut flora and environment in patients with severe systemic inflammatory response syndrome (SIRS). Twenty-nine SIRS patients, who fulfilled a serum C-reactive protein (CRP) level >10 mg/dl, received synbiotics (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) (S group) and were compared with previous observations in 26 patients without synbiotics (NS group). Analysis of fecal flora confirmed that patients in the S group had significantly greater levels of beneficial Bifidobacterium, Lactobacillus, and total organic acids (particularly short-chain fatty acids) than those in the NS group. The incidence of infectious complications such as enteritis, pneumonia, and bacteremia was significantly lower in the S group than in the NS group. Synbiotics maintain the gut flora and environment and decrease the incidence of septic complications in patients with severe SIRS. Further randomized controlled study is necessary to determine the effects of synbiotics.
Shimizu
Kentaro
K
Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita City, Osaka 565-0871, Japan. shimiken@hp-emerg.med.osaka-u.ac.jp
Ogura
Hiroshi
H
Goto
Miki
M
Asahara
Takashi
T
Nomoto
Koji
K
Morotomi
Masami
M
Matsushima
Asako
A
Tasaki
Osamu
O
Fujita
Kieko
K
Hosotsubo
Hideo
H
Kuwagata
Yasuyuki
Y
Tanaka
Hiroshi
H
Shimazu
Takeshi
T
Sugimoto
Hisashi
H
D000328:Adult; D000368:Aged; D001644:Bifidobacterium / Q000254:growth & development*; D002097:C-Reactive Protein / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D006801:Humans; D015994:Incidence; D007422:Intestines / Q000382:microbiology*; D007780:Lacticaseibacillus casei / Q000254:growth & development*; D008297:Male; D008875:Middle Aged; D009844:Oligosaccharides / Q000627:therapeutic use*; D010865:Pilot Projects; D019936:Probiotics / Q000627:therapeutic use*; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control*; D012720:Severity of Illness Index; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000628:therapy*; D016896:Treatment Outcome
D005227:Fatty Acids; D009844:Oligosaccharides; D002097:C-Reactive Protein